losartan has been researched along with n-formylmethionine leucyl-phenylalanine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andonegui, G; Geffner, JR; Giordano, M; López, DH; Nahmod, V; Raiden, S; Trevani, AS | 1 |
| Alvarez, C; Castello, L; Geffner, J; Giordano, M; Nahmod, V; Pereyra, Y; Raiden, S | 1 |
2 other study(ies) available for losartan and n-formylmethionine leucyl-phenylalanine
| Article | Year |
|---|---|
Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucyl-phenylalanine to neutrophil receptors.
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Humans; Imidazoles; Losartan; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Receptors, Angiotensin; Tetrazoles | 1997 |
Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cell Movement; Chemotaxis, Leukocyte; Hemorrhage; Losartan; Lung; Male; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 2000 |